A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT ID: NCT06534411

Last Updated: 2025-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1023 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-05

Study Completion Date

2026-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CagriSema

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 8-week dose escalation period until target dose of CagriSema is achieved and maintained for 52 weeks.

Group Type EXPERIMENTAL

Cagrilintide

Intervention Type DRUG

Participants will receive once-weekly cagrilintide subcutaneously.

Semaglutide

Intervention Type DRUG

Participants will receive once-weekly semaglutide subcutaneously.

Tirzepatide

Participants will receive once-weekly s.c injections of tirzepatide at escalating dose in a 4-week dose escalating period and maintained up to 56 weeks.

Group Type EXPERIMENTAL

Tirzepatide

Intervention Type DRUG

Participants will receive once-weekly tirzepatide subcutaneously.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cagrilintide

Participants will receive once-weekly cagrilintide subcutaneously.

Intervention Type DRUG

Semaglutide

Participants will receive once-weekly semaglutide subcutaneously.

Intervention Type DRUG

Tirzepatide

Participants will receive once-weekly tirzepatide subcutaneously.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female (sex at birth).
* Age 18 years or above at the time of signing the informed consent.
* Diagnosed with type 2 diabetes mellitus greater than or equal to (\>=) 180 days before screening.
* Stable daily dose(s) \>= 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
* Metformin
* sodium-glucose co-transporter 2 inhibitor (SGLT2i)
* Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mol \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening.
* Body mass index (BMI) \>= 30 kilogram per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Exclusion Criteria

* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
* Renal impairment with estimated Glomerular Filtration Rate less than \< 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Transparency (dept. 2834)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Diab Serwis Popenda Spółka Jawna

Chorzów, , Poland

Site Status

Cahaba Research

Pelham, Alabama, United States

Site Status

Velocity Clinical Research-Phoenix

Phoenix, Arizona, United States

Site Status

AES Tucson DRS

Tucson, Arizona, United States

Site Status

Woodland Int. Research Group

Little Rock, Arkansas, United States

Site Status

Velocity Clin Res-Chula Vista

Chula Vista, California, United States

Site Status

John Muir Physicians Network

Concord, California, United States

Site Status

Diabetes & Endocrine Specialists - La Mesa

La Mesa, California, United States

Site Status

Velocity Clin Research LA

Los Angeles, California, United States

Site Status

Desert Oasis Healthcare

Palm Springs, California, United States

Site Status

Velocity Clin Res Santa Ana

Santa Ana, California, United States

Site Status

Velocity Clin Res - Panorama

Van Nuys, California, United States

Site Status

Optumcare Clinical Trials,LLC-Golden

Colorado Springs, Colorado, United States

Site Status

FEME Medical LLC

Washington D.C., District of Columbia, United States

Site Status

Tampa Bay Medical Research

Clearwater, Florida, United States

Site Status

AGA Clinical Trial

Hialeah, Florida, United States

Site Status

Clinical Trial Services Corp

Miami, Florida, United States

Site Status

Bioclinical Research Alliance

Miami, Florida, United States

Site Status

New Horizon Research Center

Miami, Florida, United States

Site Status

South Broward Research LLC

Miramar, Florida, United States

Site Status

West Orange Endocrinology

Ocoee, Florida, United States

Site Status

Optimal Research Sites

Orange City, Florida, United States

Site Status

Javara Inc. / Privia Medical Group Georgia LLC

Fayetteville, Georgia, United States

Site Status

Clinical Invest Special_Gurnee

Gurnee, Illinois, United States

Site Status

Iowa Diabetes & Endo Res Ctr

West Des Moines, Iowa, United States

Site Status

Cotton-Oneill Diabetes and End

Topeka, Kansas, United States

Site Status

AES Minneapolis DRS

Richfield, Minnesota, United States

Site Status

Velocity Clin Res Gulfport

Gulfport, Mississippi, United States

Site Status

AES St. Louis DRS

St Louis, Missouri, United States

Site Status

Univ of Nebraska Medical CTR

Omaha, Nebraska, United States

Site Status

Velocity Clin Res Albuquerque

Albuquerque, New Mexico, United States

Site Status

Albany Medical College

Albany, New York, United States

Site Status

Carteret Medical Group

Morehead City, North Carolina, United States

Site Status

Piedmont Healthcare/Research

Statesville, North Carolina, United States

Site Status

Lillestol Research LLC

Fargo, North Dakota, United States

Site Status

Triad Research Institute

Norman, Oklahoma, United States

Site Status

Circuit Clinical - PMSI

Pottstown, Pennsylvania, United States

Site Status

Clinical Res Collaborative

Cumberland, Rhode Island, United States

Site Status

Velocity Clin Res Providence

East Greenwich, Rhode Island, United States

Site Status

Velocity Clin Res Gaffney

Gaffney, South Carolina, United States

Site Status

Holston Medical Group

Kingsport, Tennessee, United States

Site Status

Clinical Research Associates

Nashville, Tennessee, United States

Site Status

Velocity Clin Res Austin

Austin, Texas, United States

Site Status

AES Dallas DFW DRS

Dallas, Texas, United States

Site Status

UT Southwestern Medical Center - Lingvay

Dallas, Texas, United States

Site Status

JCCT- Juno NW Houston

Houston, Texas, United States

Site Status

Discovery MM Services - Houston - Broadway Street

Houston, Texas, United States

Site Status

PlanIt Research, PLLC

Houston, Texas, United States

Site Status

Sante Clinical Research

Kerrville, Texas, United States

Site Status

Aeres Clinical Research

Laredo, Texas, United States

Site Status

RGV Endocrine Center

McAllen, Texas, United States

Site Status

Privia Health Javara Clin Res.

Stephenville, Texas, United States

Site Status

J.Lewis Research Inc

Salt Lake City, Utah, United States

Site Status

Chrysalis Clinical Research

St. George, Utah, United States

Site Status

TPMG Clinical Research

Newport News, Virginia, United States

Site Status

Centro Médico CIMEL

Lanús Este, Buenos Aires, Argentina

Site Status

Centro de Investigaciones Médicas Mar del Plata

Mar del Plata, Buenos Aires, Argentina

Site Status

Fundación CESIM

Santa Rosa, La Pampa Province, Argentina

Site Status

Centro de Investigaciones Médicas Tucumán

San Miguel de Tucuimán, Tucumán Province, Argentina

Site Status

IMOBA

City of Buenos Aires, , Argentina

Site Status

Centro de Investigaciones Metabólicas

City of Buenos Aires, , Argentina

Site Status

Instituto de Investigaciones Clinicas San Nicolás

San Nicolás, , Argentina

Site Status

Paratus Clinical

Bruce, Australian Capital Territory, Australia

Site Status

Hunter Diabetes Centre

Merewether, New South Wales, Australia

Site Status

Austrials

St Leonards, New South Wales, Australia

Site Status

Momentum Clinical Research

St Leonards, New South Wales, Australia

Site Status

Roger Chih Yu Chen

Sydney, New South Wales, Australia

Site Status

Townsville University Hospital

Douglas, Queensland, Australia

Site Status

Paratus Clinical

Herston, Queensland, Australia

Site Status

Centro de Diabetes Curitiba

Curitiba, Paraná, Brazil

Site Status

Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

CPQuali Pesquisa Clínica Ltda

São Paulo, São Paulo, Brazil

Site Status

Hilltop Medical Clinic

Surrey, British Columbia, Canada

Site Status

G.A. Research Associates Ltd.

Moncton, New Brunswick, Canada

Site Status

Centricity Research Brampton

Brampton, Ontario, Canada

Site Status

Centricity Research Etobicoke

Etobicoke, Ontario, Canada

Site Status

Wharton Med Clin Trials

Hamilton, Ontario, Canada

Site Status

London Road Diagnostic Clinic and Medical Centre

Sarnia, Ontario, Canada

Site Status

Diabetes Heart Research Centre

Toronto, Ontario, Canada

Site Status

Ctr de rech Clin de Laval

Laval, Quebec, Canada

Site Status

Alpha Recherche Clinique - Clinique de Levis

Lévis, Quebec, Canada

Site Status

Centre Medical Acadie

Montreal, Quebec, Canada

Site Status

Ctr de Med Metab de Lanaudiere

Terrebonne, Quebec, Canada

Site Status

Diex Recherche Victoriaville

Victoriaville, Quebec, Canada

Site Status

Centre de Recherche Saint-Louis

Québec, , Canada

Site Status

Herz- und Diabeteszentrum NRW - Bad Oeynhausen

Bad Oeynhausen, , Germany

Site Status

Universitätsklinikum Essen - Klinik für Endokrinologie, Diabetologie und Stoffwechsel

Essen, , Germany

Site Status

Praxis am Markt Dr. Becker

Essen, , Germany

Site Status

Universitätsklinikum Freiburg - Innere Medizin II

Freiburg im Breisgau, , Germany

Site Status

Wendisch/Dahl Hamburg (DZHW)

Hamburg, , Germany

Site Status

Medicover Neuroendokrinologie MVZ München

München, , Germany

Site Status

MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin

Münster, , Germany

Site Status

Zentrum für klinische Studien Allgäu Oberschwaben

Wangen, , Germany

Site Status

Alexandra General Hospital, Therapeutic Clinic

Athens, Attica, Greece

Site Status

General Hospital Venizeleio-Pananeio - Diabetic Clinic

Heraklion, Crete, Greece

Site Status

Evangelismos Hospital

Athens, , Greece

Site Status

Iatriko Athinon 'Palaiou Falirou'

Athens, , Greece

Site Status

"Laiko" General Hospital of Athens

Goudi/Athens, , Greece

Site Status

University General Hospital of Ioannina,Internal Medicine

Ioannina, , Greece

Site Status

General Hospital of Thessaloniki 'G. Gennimatas

Thessaloniki, , Greece

Site Status

'Ippokrateio' General Hospital of Thessaloniki

Thessaloniki, , Greece

Site Status

Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

Szeged, Csongrád-Csanád, Hungary

Site Status

Komáromi Selye János Kórház

Komárom, Komárom-Esztergom, Hungary

Site Status

QUALICLINIC Egészségügyi Szolgáltató és Kutatásszervező Kft

Budapest, Pest County, Hungary

Site Status

Óbudai Egészségügyi Centrum

Budapest, Pest County, Hungary

Site Status

Szőcs Depot Egészségügyi Szolgáltató Kft.

Budapest, , Hungary

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.

Budapest, , Hungary

Site Status

PVN Kutato Kft.

Budapest, , Hungary

Site Status

MED-TIMA Kft.

Budapest, , Hungary

Site Status

Észak-Pesti Centrumkórház Honvédkórház

Budapest, , Hungary

Site Status

Endolife Specialty Hospitals

Guntur, Andhra Pradesh, India

Site Status

Ramaiah Memorial Hospital

Bengaluru, Karnataka, India

Site Status

Excel Endocrine Centre

Kolhāpur, Maharashtra, India

Site Status

Acharya Vinoba Bhave Rural Hospital, Sawangi Meghe, Wardha

Wardha, Maharashtra, India

Site Status

All India Institute of Medical Sciences (AIIMS)

New Delhi, National Capital Territory of Delhi, India

Site Status

Jawahar Lal Nehru Govt. Medical College

Ajmer, Rajasthan, India

Site Status

SMS Hospital

Jaipur, Rajasthan, India

Site Status

Diabetes, Thyroid and Endocrine Centre

Jaipur, Rajasthan, India

Site Status

Arthur Asirvatham hospital,

Madurai, Tamil Nadu, India

Site Status

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)

Puducherry, Tamil Nadu, India

Site Status

AIG Hospitals,Hyderabad

Hyderabad, Telangana, India

Site Status

Udyaan Health Care

Lucknow, Uttar Pradesh, India

Site Status

IPGME&R and SSKM Hospital

Kolkata, West Bengal, India

Site Status

Clalit sick fund Herzeliya

Herzeliya, Israel, Israel

Site Status

Rambam MC - Diabetes and obesity center of excellence

Haifa, , Israel

Site Status

Wolfson MC - Diabetes Clinic

Holon, , Israel

Site Status

Hadassah Ein Karam MC - Diabetes Unit

Jerusalem, , Israel

Site Status

Rabin MC Beilinson - Endo unit

Petah Tikva, , Israel

Site Status

Sourasky MC - Institute of Endocrinology, metabolism and hypertension

Tel Aviv, , Israel

Site Status

Sheba MC - Endocrinology Clinic

Tel Litwinsky, , Israel

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, , Poland

Site Status

Specjalistyczny Gabinet Diabetologiczny Rumianowski Radosław

Gorzów Wielkopolski, , Poland

Site Status

Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A.

Lodz, , Poland

Site Status

Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.

Olsztyn, , Poland

Site Status

Kiepury Clinic MALGORZATA JARNOT SPECJALISTYCZNA PRAKTYKA GINEKOLOGICZNO-POLOZNICZA

Sosnowiec, , Poland

Site Status

Centrum Medyczne Oporow

Wroclaw, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko

Zabrze, , Poland

Site Status

Diabdana S.R.L.

Oradea, Bihor County, Romania

Site Status

Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

Bucharest, Bucurestii, Romania

Site Status

CMI Dr Pop Lavinia

Baia Mare, Maramureş, Romania

Site Status

Sc Mediab Srl

Târgu Mureş, Mureș County, Romania

Site Status

SC Nutrilife SRL

Bucharest, , Romania

Site Status

Diabet Med SRL

Bucharest, , Romania

Site Status

Sanamed Hospital SRL

Bucharest, , Romania

Site Status

Clinica Korall S.R.L. Satu Mare

Satu Mare, , Romania

Site Status

Clinica Universitaria de Navarra

Pamplona, Navarre, Spain

Site Status

Centro Periferico De Especialidades Bola Azul

Almería, , Spain

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario San Cecilio

Granada, , Spain

Site Status

Clínica Nuevas Tecnologías en Diabetes y Endocrinología

Seville, , Spain

Site Status

Hospital Clínico de Valladolid

Valladolid, , Spain

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Chang Gung Memorial Hospital - Kaohsiung Branch

Kaohsiung City, , Taiwan

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaoshiung, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital Linkou

Taoyuan, , Taiwan

Site Status

Chang Gung Memorial Hospital, Linkou

Taoyuan District, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Canada Germany Greece Hungary India Israel Poland Romania Spain Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1300-2590

Identifier Type: OTHER

Identifier Source: secondary_id

2023-509600-15

Identifier Type: OTHER

Identifier Source: secondary_id

NN9388-7741

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.